BlossomHill Therapeutics, Inc. (NASDAQ:BLSM – Get Free Report) General Counsel Vincent Paul Liptak bought 2,200 shares of BlossomHill Therapeutics stock in a transaction dated Monday, August 10th. The stock was purchased at an average price of $16.00 per share, with a total value of $35,200.00. Following the purchase, the general counsel directly owned 111,412 shares in the company, valued at approximately $1,782,592. This trade represents a 2.01% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available through this link.
Vincent Paul Liptak also recently made the following trade(s):
- On Friday, August 7th, Vincent Paul Liptak purchased 2,500 shares of BlossomHill Therapeutics stock. The shares were purchased at an average price of $15.80 per share, for a total transaction of $39,500.00.
BlossomHill Therapeutics Price Performance
NASDAQ BLSM traded down $0.01 during trading hours on Monday, hitting $15.99. 417,968 shares of the stock were exchanged. BlossomHill Therapeutics, Inc. has a 12-month low of $15.25 and a 12-month high of $17.25.
See Also
- Five stocks we like better than BlossomHill Therapeutics
- SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
- 3 Dividend Champion Utilities for a Market That Can’t Sit Still
- These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
- First Solar’s Profit Engine Faces a New Policy Test in Washington
Receive News & Ratings for BlossomHill Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BlossomHill Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
